FREENOME BCG MATRIX TEMPLATE RESEARCH
Unlock Strategic Clarity
Freenome's BCG Matrix snapshot highlights where its diagnostics and pipeline assets likely sit across Stars, Question Marks, Cash Cows, and Dogs, revealing early winners and resource drains; this concise view points to growth bets in early cancer-detection markets and capital allocation risks for late-stage programs. Purchase the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and a ready-to-use Word and Excel package that turns these signals into actionable investment and strategic choices.
Stars
SimpleScreen™ CRC Version 1.0
SimpleScreen™ CRC Version 1.0 is Freenome's flagship blood test for colorectal cancer, under FDA review with a decision expected mid-2026; PREEMPT (49,000 patients) showed 81.1% sensitivity and 90.4% specificity.
Its Star status is reinforced by an $885 million commercialization deal with Exact Sciences, who will deploy Cologuard's U.S. infrastructure to scale uptake and revenue potential.
AI-Multiomics Discovery Platform
Freenome's AI-multiomics platform-combining genomic, epigenomic, and proteomic data with ML-drives its pipeline and qualifies as a BCG Star due to high growth and market leadership.
In January 2026 Freenome partnered with NVIDIA to speed deep-learning training for cancer signatures, cutting model training time by reported multiples.
The platform underpins future products, has attracted over $1.3 billion in funding to date, and supports a 2025 R&D spend of approximately $220 million.
International 'Kitted' Test Partnership
Through a November 2025 deal worth over $200 million, Roche bought exclusive rights to commercialize Freenome's kitted liquid biopsy tests outside the U.S., enabling decentralized testing in regions lacking centralized labs and accelerating global rollout without Freenome building international labs.
Strategic Data Moat
Freenome's multimodal data moat-built from ~30,000+ clinical samples (2025) and partnerships with Roche and Exact Sciences-boosts AI sensitivity as datasets grow, creating a virtuous cycle of model improvement and product performance.
With the liquid biopsy market forecast at $6 billion by 2029, Freenome's data leadership is a critical barrier to entry that supports pricing power and diagnostic accuracy gains.
- 30,000+ clinical samples (2025)
- Commercial partners: Roche, Exact Sciences
- AI accuracy improves with sample volume
- Market proj: $6B by 2029
Public Listing via PCSC SPAC
The December 2025 merger with Perceptive Capital Solutions Corp (PCSC) delivered a $330 million cash infusion and Nasdaq listing under FRNM, funding Freenome's 2026 commercial launch and R&D ramp while increasing public scrutiny and cash burn.
The $1.1 billion post‑deal valuation positions Freenome as a leading specialized medtech player in a high‑growth CRC screening market projected to reach $8.5B by 2030.
- $330M pro‑ceeds from PCSC merger
- Nasdaq ticker: FRNM
- $1.1B post‑deal valuation
- Funds 2026 launch + continued R&D
Freenome: BCG Star-FDA‑near CRC test, $1.1B valuation, $885M deals, robust data moat
SimpleScreen™ CRC (81.1% sens, 90.4% spec; FDA decision mid‑2026) plus $885M Exact Sciences and Roche deals, $330M SPAC proceeds, $1.1B post‑deal valuation, $220M R&D (2025), 30,000+ samples (2025) - positions Freenome as a BCG Star: high growth, market leadership, strong data moat and commercialization scale.
| Metric | Value (2025/2026) |
|---|---|
| Sensitivity / Specificity | 81.1% / 90.4% |
| Deals | $885M Exact, $200M+ Roche |
| Funding / Valuation | $330M SPAC; $1.1B |
| R&D spend | $220M |
| Samples | 30,000+ |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix for Freenome: strategic guidance on Stars, Cash Cows, Question Marks, and Dogs with investment, hold, or divest recommendations.
Customizable Excel Spreadsheet
One-page Freenome BCG Matrix placing each business unit in a quadrant for quick strategic clarity.
Cash Cows
Exact Sciences $75M Upfront Payment
The $75M upfront from Exact Sciences in late 2025 provides Freenome with a non-dilutive, realized cash inflow that acts as a short-term cash cow-covering FDA submission and administrative expenses (estimated $30-50M for 2025-2026 filings) while requiring minimal ongoing capex to maintain IP rights.
Roche Equity Investment & R&D Support
Roche's cumulative investments-totaling roughly $150 million to date and including a $75 million equity instrument in late 2025-provide steady capital support for Freenome's multiomics platform.
These funds are being used to fund operational infrastructure-labs, bioinformatics, and regulatory work-to "milk" the platform ahead of planned 2026 launches, preserving runway.
The partnership de-risks Freenome's balance sheet by covering ~60-70% of near-term cash burn, lowering the need for immediate dilutive financing while commercial sales scale.
CLIA-Certified Laboratory Services
Freenome's CLIA-certified high-complexity lab in Brisbane, CA, processes clinical-trial and biopharma samples, generating steady utility and supporting $0-$50M run-rate service revenue (2025 estimate) while not yet reaching blockbuster scale.
The mature lab is a durable asset with established SOPs and CAP/CLIA accreditation, handling thousands of samples annually (≈12,000 in 2024) and reducing partner onboarding time by ~30%.
Milestone Payment Pipeline
Freenome has structured deals totalling up to $825 million in contingent milestone payments-$700 million from Exact Sciences and $125+ million from Roche-acting as near-term high-margin cash cows once USPSTF and regulatory milestones clear, funding R&D and commercialization of Question Mark pipeline products.
- $700M Exact Sciences potential
- $125M+ Roche potential
- High gross margins once recognized
- Funds next-gen product development
Intellectual Property Portfolio
Freenome's extensive patent estate on AI/ML algorithms and multiomic signatures is a mature cash cow, enabling licensing deals that generate recurring revenue with minimal incremental R&D, supporting its $1.1 billion market valuation as of 2025.
In 2025 Freenome reported IP-driven licensing potential worth an estimated $45-70M annualized revenue in industry models, lowering operating leverage and preserving R&D spend for pipeline programs.
- Patents: dozens covering algorithms and signatures
- Valuation support: $1.1B (2025)
- Estimated licensing revenue: $45-70M/year
- Low incremental R&D for licensed tech
Deal funds 60-70% burn, covers FDA filing; $45-70M/yr IP + $825M milestones
Exact Sciences $75M (late 2025) + Roche $150M cumulative fund 60-70% of near-term burn, cover $30-50M FDA filing costs, Brisbane CLIA lab ~$0-50M 2025 service revenue, IP licensing potential $45-70M/yr; contingent milestones up to $825M support commercialization and R&D.
| Item | 2025 Value |
|---|---|
| Exact Sciences upfront | $75M |
| Roche cumulative | $150M |
| FDA filing cost est. | $30-50M |
| Brisbane lab revenue est. | $0-50M |
| IP licensing est. | $45-70M/yr |
| Contingent milestones | Up to $825M |
What You're Viewing Is Included
Freenome BCG Matrix
The preview you're viewing is the exact Freenome BCG Matrix file you'll receive after purchase-no watermarks, no placeholders, just the fully formatted, analysis-ready report designed for immediate use in presentations, strategy sessions, or board packs.
Original: $10.00
-65%$10.00
$3.50FREENOME BCG MATRIX TEMPLATE RESEARCH
Unlock Strategic Clarity
Freenome's BCG Matrix snapshot highlights where its diagnostics and pipeline assets likely sit across Stars, Question Marks, Cash Cows, and Dogs, revealing early winners and resource drains; this concise view points to growth bets in early cancer-detection markets and capital allocation risks for late-stage programs. Purchase the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and a ready-to-use Word and Excel package that turns these signals into actionable investment and strategic choices.
Stars
SimpleScreen™ CRC Version 1.0
SimpleScreen™ CRC Version 1.0 is Freenome's flagship blood test for colorectal cancer, under FDA review with a decision expected mid-2026; PREEMPT (49,000 patients) showed 81.1% sensitivity and 90.4% specificity.
Its Star status is reinforced by an $885 million commercialization deal with Exact Sciences, who will deploy Cologuard's U.S. infrastructure to scale uptake and revenue potential.
AI-Multiomics Discovery Platform
Freenome's AI-multiomics platform-combining genomic, epigenomic, and proteomic data with ML-drives its pipeline and qualifies as a BCG Star due to high growth and market leadership.
In January 2026 Freenome partnered with NVIDIA to speed deep-learning training for cancer signatures, cutting model training time by reported multiples.
The platform underpins future products, has attracted over $1.3 billion in funding to date, and supports a 2025 R&D spend of approximately $220 million.
International 'Kitted' Test Partnership
Through a November 2025 deal worth over $200 million, Roche bought exclusive rights to commercialize Freenome's kitted liquid biopsy tests outside the U.S., enabling decentralized testing in regions lacking centralized labs and accelerating global rollout without Freenome building international labs.
Strategic Data Moat
Freenome's multimodal data moat-built from ~30,000+ clinical samples (2025) and partnerships with Roche and Exact Sciences-boosts AI sensitivity as datasets grow, creating a virtuous cycle of model improvement and product performance.
With the liquid biopsy market forecast at $6 billion by 2029, Freenome's data leadership is a critical barrier to entry that supports pricing power and diagnostic accuracy gains.
- 30,000+ clinical samples (2025)
- Commercial partners: Roche, Exact Sciences
- AI accuracy improves with sample volume
- Market proj: $6B by 2029
Public Listing via PCSC SPAC
The December 2025 merger with Perceptive Capital Solutions Corp (PCSC) delivered a $330 million cash infusion and Nasdaq listing under FRNM, funding Freenome's 2026 commercial launch and R&D ramp while increasing public scrutiny and cash burn.
The $1.1 billion post‑deal valuation positions Freenome as a leading specialized medtech player in a high‑growth CRC screening market projected to reach $8.5B by 2030.
- $330M pro‑ceeds from PCSC merger
- Nasdaq ticker: FRNM
- $1.1B post‑deal valuation
- Funds 2026 launch + continued R&D
Freenome: BCG Star-FDA‑near CRC test, $1.1B valuation, $885M deals, robust data moat
SimpleScreen™ CRC (81.1% sens, 90.4% spec; FDA decision mid‑2026) plus $885M Exact Sciences and Roche deals, $330M SPAC proceeds, $1.1B post‑deal valuation, $220M R&D (2025), 30,000+ samples (2025) - positions Freenome as a BCG Star: high growth, market leadership, strong data moat and commercialization scale.
| Metric | Value (2025/2026) |
|---|---|
| Sensitivity / Specificity | 81.1% / 90.4% |
| Deals | $885M Exact, $200M+ Roche |
| Funding / Valuation | $330M SPAC; $1.1B |
| R&D spend | $220M |
| Samples | 30,000+ |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix for Freenome: strategic guidance on Stars, Cash Cows, Question Marks, and Dogs with investment, hold, or divest recommendations.
Customizable Excel Spreadsheet
One-page Freenome BCG Matrix placing each business unit in a quadrant for quick strategic clarity.
Cash Cows
Exact Sciences $75M Upfront Payment
The $75M upfront from Exact Sciences in late 2025 provides Freenome with a non-dilutive, realized cash inflow that acts as a short-term cash cow-covering FDA submission and administrative expenses (estimated $30-50M for 2025-2026 filings) while requiring minimal ongoing capex to maintain IP rights.
Roche Equity Investment & R&D Support
Roche's cumulative investments-totaling roughly $150 million to date and including a $75 million equity instrument in late 2025-provide steady capital support for Freenome's multiomics platform.
These funds are being used to fund operational infrastructure-labs, bioinformatics, and regulatory work-to "milk" the platform ahead of planned 2026 launches, preserving runway.
The partnership de-risks Freenome's balance sheet by covering ~60-70% of near-term cash burn, lowering the need for immediate dilutive financing while commercial sales scale.
CLIA-Certified Laboratory Services
Freenome's CLIA-certified high-complexity lab in Brisbane, CA, processes clinical-trial and biopharma samples, generating steady utility and supporting $0-$50M run-rate service revenue (2025 estimate) while not yet reaching blockbuster scale.
The mature lab is a durable asset with established SOPs and CAP/CLIA accreditation, handling thousands of samples annually (≈12,000 in 2024) and reducing partner onboarding time by ~30%.
Milestone Payment Pipeline
Freenome has structured deals totalling up to $825 million in contingent milestone payments-$700 million from Exact Sciences and $125+ million from Roche-acting as near-term high-margin cash cows once USPSTF and regulatory milestones clear, funding R&D and commercialization of Question Mark pipeline products.
- $700M Exact Sciences potential
- $125M+ Roche potential
- High gross margins once recognized
- Funds next-gen product development
Intellectual Property Portfolio
Freenome's extensive patent estate on AI/ML algorithms and multiomic signatures is a mature cash cow, enabling licensing deals that generate recurring revenue with minimal incremental R&D, supporting its $1.1 billion market valuation as of 2025.
In 2025 Freenome reported IP-driven licensing potential worth an estimated $45-70M annualized revenue in industry models, lowering operating leverage and preserving R&D spend for pipeline programs.
- Patents: dozens covering algorithms and signatures
- Valuation support: $1.1B (2025)
- Estimated licensing revenue: $45-70M/year
- Low incremental R&D for licensed tech
Deal funds 60-70% burn, covers FDA filing; $45-70M/yr IP + $825M milestones
Exact Sciences $75M (late 2025) + Roche $150M cumulative fund 60-70% of near-term burn, cover $30-50M FDA filing costs, Brisbane CLIA lab ~$0-50M 2025 service revenue, IP licensing potential $45-70M/yr; contingent milestones up to $825M support commercialization and R&D.
| Item | 2025 Value |
|---|---|
| Exact Sciences upfront | $75M |
| Roche cumulative | $150M |
| FDA filing cost est. | $30-50M |
| Brisbane lab revenue est. | $0-50M |
| IP licensing est. | $45-70M/yr |
| Contingent milestones | Up to $825M |
What You're Viewing Is Included
Freenome BCG Matrix
The preview you're viewing is the exact Freenome BCG Matrix file you'll receive after purchase-no watermarks, no placeholders, just the fully formatted, analysis-ready report designed for immediate use in presentations, strategy sessions, or board packs.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Unlock Strategic Clarity
Freenome's BCG Matrix snapshot highlights where its diagnostics and pipeline assets likely sit across Stars, Question Marks, Cash Cows, and Dogs, revealing early winners and resource drains; this concise view points to growth bets in early cancer-detection markets and capital allocation risks for late-stage programs. Purchase the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and a ready-to-use Word and Excel package that turns these signals into actionable investment and strategic choices.
Stars
SimpleScreen™ CRC Version 1.0
SimpleScreen™ CRC Version 1.0 is Freenome's flagship blood test for colorectal cancer, under FDA review with a decision expected mid-2026; PREEMPT (49,000 patients) showed 81.1% sensitivity and 90.4% specificity.
Its Star status is reinforced by an $885 million commercialization deal with Exact Sciences, who will deploy Cologuard's U.S. infrastructure to scale uptake and revenue potential.
AI-Multiomics Discovery Platform
Freenome's AI-multiomics platform-combining genomic, epigenomic, and proteomic data with ML-drives its pipeline and qualifies as a BCG Star due to high growth and market leadership.
In January 2026 Freenome partnered with NVIDIA to speed deep-learning training for cancer signatures, cutting model training time by reported multiples.
The platform underpins future products, has attracted over $1.3 billion in funding to date, and supports a 2025 R&D spend of approximately $220 million.
International 'Kitted' Test Partnership
Through a November 2025 deal worth over $200 million, Roche bought exclusive rights to commercialize Freenome's kitted liquid biopsy tests outside the U.S., enabling decentralized testing in regions lacking centralized labs and accelerating global rollout without Freenome building international labs.
Strategic Data Moat
Freenome's multimodal data moat-built from ~30,000+ clinical samples (2025) and partnerships with Roche and Exact Sciences-boosts AI sensitivity as datasets grow, creating a virtuous cycle of model improvement and product performance.
With the liquid biopsy market forecast at $6 billion by 2029, Freenome's data leadership is a critical barrier to entry that supports pricing power and diagnostic accuracy gains.
- 30,000+ clinical samples (2025)
- Commercial partners: Roche, Exact Sciences
- AI accuracy improves with sample volume
- Market proj: $6B by 2029
Public Listing via PCSC SPAC
The December 2025 merger with Perceptive Capital Solutions Corp (PCSC) delivered a $330 million cash infusion and Nasdaq listing under FRNM, funding Freenome's 2026 commercial launch and R&D ramp while increasing public scrutiny and cash burn.
The $1.1 billion post‑deal valuation positions Freenome as a leading specialized medtech player in a high‑growth CRC screening market projected to reach $8.5B by 2030.
- $330M pro‑ceeds from PCSC merger
- Nasdaq ticker: FRNM
- $1.1B post‑deal valuation
- Funds 2026 launch + continued R&D
Freenome: BCG Star-FDA‑near CRC test, $1.1B valuation, $885M deals, robust data moat
SimpleScreen™ CRC (81.1% sens, 90.4% spec; FDA decision mid‑2026) plus $885M Exact Sciences and Roche deals, $330M SPAC proceeds, $1.1B post‑deal valuation, $220M R&D (2025), 30,000+ samples (2025) - positions Freenome as a BCG Star: high growth, market leadership, strong data moat and commercialization scale.
| Metric | Value (2025/2026) |
|---|---|
| Sensitivity / Specificity | 81.1% / 90.4% |
| Deals | $885M Exact, $200M+ Roche |
| Funding / Valuation | $330M SPAC; $1.1B |
| R&D spend | $220M |
| Samples | 30,000+ |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix for Freenome: strategic guidance on Stars, Cash Cows, Question Marks, and Dogs with investment, hold, or divest recommendations.
Customizable Excel Spreadsheet
One-page Freenome BCG Matrix placing each business unit in a quadrant for quick strategic clarity.
Cash Cows
Exact Sciences $75M Upfront Payment
The $75M upfront from Exact Sciences in late 2025 provides Freenome with a non-dilutive, realized cash inflow that acts as a short-term cash cow-covering FDA submission and administrative expenses (estimated $30-50M for 2025-2026 filings) while requiring minimal ongoing capex to maintain IP rights.
Roche Equity Investment & R&D Support
Roche's cumulative investments-totaling roughly $150 million to date and including a $75 million equity instrument in late 2025-provide steady capital support for Freenome's multiomics platform.
These funds are being used to fund operational infrastructure-labs, bioinformatics, and regulatory work-to "milk" the platform ahead of planned 2026 launches, preserving runway.
The partnership de-risks Freenome's balance sheet by covering ~60-70% of near-term cash burn, lowering the need for immediate dilutive financing while commercial sales scale.
CLIA-Certified Laboratory Services
Freenome's CLIA-certified high-complexity lab in Brisbane, CA, processes clinical-trial and biopharma samples, generating steady utility and supporting $0-$50M run-rate service revenue (2025 estimate) while not yet reaching blockbuster scale.
The mature lab is a durable asset with established SOPs and CAP/CLIA accreditation, handling thousands of samples annually (≈12,000 in 2024) and reducing partner onboarding time by ~30%.
Milestone Payment Pipeline
Freenome has structured deals totalling up to $825 million in contingent milestone payments-$700 million from Exact Sciences and $125+ million from Roche-acting as near-term high-margin cash cows once USPSTF and regulatory milestones clear, funding R&D and commercialization of Question Mark pipeline products.
- $700M Exact Sciences potential
- $125M+ Roche potential
- High gross margins once recognized
- Funds next-gen product development
Intellectual Property Portfolio
Freenome's extensive patent estate on AI/ML algorithms and multiomic signatures is a mature cash cow, enabling licensing deals that generate recurring revenue with minimal incremental R&D, supporting its $1.1 billion market valuation as of 2025.
In 2025 Freenome reported IP-driven licensing potential worth an estimated $45-70M annualized revenue in industry models, lowering operating leverage and preserving R&D spend for pipeline programs.
- Patents: dozens covering algorithms and signatures
- Valuation support: $1.1B (2025)
- Estimated licensing revenue: $45-70M/year
- Low incremental R&D for licensed tech
Deal funds 60-70% burn, covers FDA filing; $45-70M/yr IP + $825M milestones
Exact Sciences $75M (late 2025) + Roche $150M cumulative fund 60-70% of near-term burn, cover $30-50M FDA filing costs, Brisbane CLIA lab ~$0-50M 2025 service revenue, IP licensing potential $45-70M/yr; contingent milestones up to $825M support commercialization and R&D.
| Item | 2025 Value |
|---|---|
| Exact Sciences upfront | $75M |
| Roche cumulative | $150M |
| FDA filing cost est. | $30-50M |
| Brisbane lab revenue est. | $0-50M |
| IP licensing est. | $45-70M/yr |
| Contingent milestones | Up to $825M |
What You're Viewing Is Included
Freenome BCG Matrix
The preview you're viewing is the exact Freenome BCG Matrix file you'll receive after purchase-no watermarks, no placeholders, just the fully formatted, analysis-ready report designed for immediate use in presentations, strategy sessions, or board packs.
